about
sameAs
The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the risk and prognosis of portuguese patients with non-small cell lung cancer.Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies.[Massive subcutaneous emphysema--management using subcutaneous drains].Sialylation regulates galectin-3/ligand interplay during mammary tumour progression--a case of targeted uncloaking.Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis.Loci identified through genome-wide association studies and lung cancer risk: is there anything more?Non-small cell lung cancer in young patients--a retrospective analysis of 10 years in a tertiary university hospital.Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study.Lung cancer in Northern Portugal: A hospital-based study.Pulmonary rehabilitation in patients with bronchiectasis: pulmonary function, arterial blood gases, and the 6-minute walk test.How to write a scientific paper—Writing the methods sectionMUC1 expression in canine malignant mammary tumours and relationship to clinicopathological featuresEGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective studyChronic Bacterial Infection Prevalence, Risk Factors, and Characteristics: A Bronchiectasis Population-Based Prospective Study[Efficacy and patterns of ambulatory oxygen usage - experience of a university hospital]Discordance between old and new criteria for stratifying patients with COPDCirculating Tumor DNA: A Step into the Future of Cancer ManagementCharacterisation of morbidity in a COPD hospital cohortIs an Early Diagnosis of COPD Clinically Useful?Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical ImplementationCOPD: misuse of inhaler devices in clinical practiceCOPD: Analysing factors associated with a successful treatment
P50
Q34988362-D1082EB4-17FC-4EE9-9E60-AEA19541476CQ37919918-6A148C5D-32A5-4E0D-A9E5-ED999266C5ADQ39286676-F41F6120-1537-42D5-A809-5647373B3C59Q39429457-5DE2691F-799C-4F77-BD2F-0226C50CBC28Q39686520-0DC62E3A-D334-4D02-825A-45439C213DE7Q45761117-1F275DE6-031C-4B83-BFC2-8120F48D3EFDQ47953918-8BAA4870-5E87-476A-AD7C-887DBAD78D1EQ47972274-539E9B9E-F8D4-4D2A-A738-7C1D507A3721Q51193846-06793BE7-5DCA-44F7-B8D2-21C01BF7E29AQ51334181-95289A23-98E0-4D12-9428-34E784A3FA63Q57569824-FE4B3E83-AFCA-4F04-BC32-4E9CD1266B7EQ61974088-F2B8B04B-F2C6-46AB-801A-F0FF4D10822BQ62127975-43CD936E-DEDB-4065-8A04-05A1198CA0FFQ64057438-39DE4AB1-2DA1-4850-8C7B-03F11914E308Q84212734-52D04605-15AD-47A9-9CF6-73A17B01DB8CQ90745281-5FBD0CC1-1988-48DF-B1E6-581EFDD11201Q92247639-8DE5FCCE-177E-4E0C-B594-433454A96EAEQ92472112-29730F48-7F7F-4C82-9427-B36B352F4169Q92755465-2F73C574-BD2B-44D0-B95A-07BC0A65EC76Q92826289-2B39E414-DC38-46A5-840F-33803952C376Q92861433-7B69CE3C-2F9D-4A36-B079-17FA40FCBC37Q92915259-A1AF7DFF-14CA-4AFB-A081-20D79A9F1237
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Venceslau Hespanhol
@ast
Venceslau Hespanhol
@en
Venceslau Hespanhol
@es
Venceslau Hespanhol
@nl
Venceslau Hespanhol
@sl
type
label
Venceslau Hespanhol
@ast
Venceslau Hespanhol
@en
Venceslau Hespanhol
@es
Venceslau Hespanhol
@nl
Venceslau Hespanhol
@sl
prefLabel
Venceslau Hespanhol
@ast
Venceslau Hespanhol
@en
Venceslau Hespanhol
@es
Venceslau Hespanhol
@nl
Venceslau Hespanhol
@sl
P106
P1153
6602524273
P21
P31
P496
0000-0001-6577-0063